Kainos Medicine, Inc. (KOSDAQ:284620)

Market Cap	39.44B
Revenue (ttm)	820.50M
Net Income (ttm)	-11.83B
Shares Out	33.09M
EPS (ttm)	-421.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,186,810
Average Volume	440,149
Open	1,390.00
Previous Close	1,270.00
Day's Range	1,126.00 - 1,490.00
52-Week Range	960.00 - 6,000.00
Beta	1.29
RSI	61.11
Earnings Date	n/a

About Kainos Medicine

Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 284620